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Background: Arterial stiffness is an important predictor of cardiovascular risk besides classic 
cardiovascular risk factors. Previous studies showed that arterial stiffness is increased in patients 
with COPD compared to healthy controls and exercise training may reduce arterial stiffness. 
Since physical inactivity is frequently observed in patients with COPD and exercise training 
may improve arterial stiffness, we hypothesized that low daily physical activity may be associ-
ated with increased arterial stiffness.
Methods: In 123 patients with COPD (72% men; mean [standard deviation] age: 62 [7.5] years; 
median [quartile] forced expiratory volume in 1 second 35 [27/65] %predicted), arterial stiffness 
was assessed by augmentation index (AI). Daily physical activity level (PAL) was measured 
by an activity monitor (SenseWear Pro™) .1 week. The association between AI and PAL was 
investigated by univariate and multivariate regression analysis, taking into account disease-
specific characteristics and comorbidities.
Results: Patients suffered from moderate (35%), severe (32%), and very severe (33%) COPD, 
and 22% were active smokers. Median (quartile) PAL was 1.4 (1.3/1.5) and mean (standard 
deviation) AI 26% (9.2%). PAL showed a negative association with AI (B=-9.32, P=0.017) 
independent of age, sex, blood pressure, and airflow limitation.
Conclusion: In COPD patients, a higher PAL seems to favorably influence arterial stiffness 
and therefore may reduce cardiovascular risk.
Clinical Trial Registration: www.ClinicalTrials.gov, NCT01527773
Keywords: activity monitor, airflow limitation, COPD, physical activity level
Introduction
COPD is associated with an increased risk of cardiovascular morbidity and mortality.1–3 
Vascular dysfunction may represent a mechanism through which COPD leads to cardio-
vascular disease. Arterial stiffness is increased even in early stages of atherosclerosis 
and thus may be helpful in identifying patients at increased vascular risk.4 Pulse wave 
analysis-derived measures of arterial stiffness such as pulse wave velocity (PWV) and 
augmentation index (AI) have been shown to independently predict cardiovascular 
risk and mortality.5–7 In COPD patients, arterial stiffness assessed by PWV and AI 
has been shown to be elevated compared to healthy controls.8,9 Previous studies in 
COPD patients showed incongruent results regarding the association between arte-
rial stiffness, airflow limitation,9,10 and systemic inflammation.9,11 A recent summary 
on arterial stiffness in COPD postulated that these processes may lead to vascular 
remodeling and atherosclerosis progression finally leading to cardiovascular events.12 
Physical inactivity is associated with a higher risk for cardiovascular disease in the 
general population.13 Physical activity (PA) represents any bodily movement produced 
by skeletal muscles that results in energy expenditure and received more attention in 
COPD-related research in recent years. Most patients with COPD present with remark-
ably low levels of PA compared to subjects without COPD, even in mild to moderate 
stages of the disease.14 In longitudinal cohort studies, regular PA has been shown to 
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reduce hospital admission and mortality in COPD patients.15 
In a previous study evaluating endothelial function in COPD 
patients, we found that PA showed a positive independent 
effect on endothelial function.3 Therefore, the level of daily 
PA may be an important determinant of vascular damage in 
patients with COPD. However, endothelial dysfunction and 
arterial stiffness represent two different aspects of vascular 
health. While arterial stiffness is determined mainly by the 
elastin to collagen ratio in the arterial wall, the endothelium 
senses change in hemodynamic signals and respond by 
release of relaxing factors including nitric oxide that plays 
a key role in maintaining vascular homeostasis.16 Therefore, 
we hypothesized that a lower level of daily PA is associated 
with increased arterial stiffness in a heterogeneous group of 
COPD patients.
Methods
subjects
This study was performed as a substudy of The Obstruc-
tive Pulmonary Disease Outcomes Cohort of Switzerland 
(TOPDOCS). TOPDOCS is an ongoing prospective, non-
interventional cohort study. Patients were recruited during 
ambulatory visits in the pulmonary clinics or during hospital 
stay. Patients aged between 40 years and 75 years with objec-
tively confirmed COPD according to GOLD guidelines17 
were assessed for eligibility between October 2011 and 
September 2014. Patients were excluded if they had suffered 
from a COPD exacerbation within the last 6 weeks or if 
they suffered from mental or physical disability precluding 
informed consent or compliance with the protocol.
The study was conducted in accordance with the Dec-
laration of Helsinki of the World Medical Association. The 
Ethics Committee of the Canton of Zurich approved the study 
(EK-ZH-NR: 2011-0106), and the study was registered at 
www.ClinicalTrials.gov, NCT01527773. All subjects gave 
written informed consent to participate.
Measurements
arterial stiffness
After resting 10 minutes in supine position, radial artery 
pulse waveforms were recorded with a pressure tonometer 
(SphygmoCor System; AtCor Medical, Sydney, NSW, 
Australia). Approximately ten radial pulse waves were 
measured to generate a corresponding central aortic pressure 
waveform with a validated mathematical transfer function.18 
With an algorithm, the inflection point of the aortic pressure 
waveform can be determined, which corresponds to the onset 
of the reflected wave returning from peripheral arteries and 
divides the aortic pressure wave into an early and late systolic 
peak. AI as a measure for peripheral arterial wave reflection 
quantifies augmentation of central aortic pressure and is 
calculated as the difference between the second (P2) and first 
(P1) systolic peak pressure and is expressed as percentage of 
the central pulse pressure (PP): AI (%) = [(P2-P1)/PP] ×100 
(Figure 1). AI is corrected to a heart rate of 75 bpm since 
AI is influenced by heart rate.19 The faster the pulse wave 
returns from the periphery, the stiffer the arteries are and 
the higher the AI. Following the recommendations of the 
manufacturer, a measurement was only accepted when the 
operator index (with a range from 0 to 100 with increasing 
quality) was .80.
Physical activity
Physical activity level (PAL) and the number of steps per day 
were assessed by a multisensory band (SenseWear Pro™; 
Bodymedia Inc., Pittsburgh, PA, USA), which was worn on 
the upper left arm over the triceps muscle. The SenseWear 
armband has been validated to be a stable measure of walk-
ing and daily PA in patients with COPD.20 Patient’s data 
were recorded .7 consecutive days. The threshold for valid 
data from the armband was set at 4 days with a minimum 
of 22.5 hours/day. PAL is an objective measure of daily PA 
and is defined as the total energy expenditure divided by the 
resting metabolic rate.14 A PAL of $1.70 defines an active 
person, a PAL between 1.40 and 1.69 a sedentary person, and 
,1.40 defines a very inactive person.14,21 The number of steps 
per day was recorded by an inbuilt biaxial accelerometer.22
lung function
All participants underwent standard pulmonary functional 
testing according to American Thoracic Society guidelines 
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Figure 1 The augmentation index (aI) is calculated as the difference between the 
second (P2) and first (P1) systolic peak pressure and is expressed as percentage of 
the central PP: aI (%) = [(P2-P1)/PP] ×100.
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to measure forced expiratory volume in 1 second (FEV
1
), 
forced vital capacity,23 diffusion capacity (TLco), residual 
volume (RV), total lung capacity (TLC), and hyperinflation 
(RV/TLC).24 Values after bronchodilatation are reported.
Data analysis and statistics
All results are shown as mean (standard deviation [SD]) and 
median (quartiles) unless otherwise stated. Statistical analy-
sis was performed with STATA 13 (StataCorp LP, College 
Station, TX, USA).
Univariate regression analysis was used to investigate 
associations between AI (dependent variable) and PAL as 
well as possible predictors for AI, such as age, sex, body 
mass index (BMI), smoking, blood pressure, lung function, 
cardiovascular comorbidities, and c-reactive protein. To fur-
ther investigate the independent association between AI and 
PAL, multivariate analysis involved regression of variables 
that showed a univariate regression P-value of ,0.1. To take 
into account a nonlinear association between AI and age, the 
squared term of age (age × age) was included in the analysis. 
Residual analysis of the model was performed to check the 
regression assumptions. A two-sided P-value of ,0.05 was 
considered to be statistically significant.
Results
study participants and baseline 
characteristics
A total of 123 COPD patients entered the final analysis 
(Figure 2). Of those patients, 35% were classified as GOLD 
1/2, 32% GOLD 3, and 33% GOLD 4. According to the 
novel GOLD classification (www.goldcopd.org) considering 
symptoms and exacerbations, 11% were classified as risk 
group A, 24% group B, 4% group C, and 61% group D. The 
mean (SD) age was 62 (7.5) years. Sixty-six percent of the 
patients had a known cardiovascular comorbidity. Seventy-
five percent of the patients used long-acting bronchodilators, 
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Figure 2 Study flow.
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and 56% also inhaled a corticosteroid on a regular base. 
Blood pressure-lowering medications were taken by 53% 
of the patients, and 36% used lipid-lowering medications. 
Median (quartile) PAL was 1.4 (1.3/1.5) and mean (SD) AI 
26% (9.2%). The detailed patient characteristics are shown 
in Table 1.
Predictors of aI
AI was negatively associated with sex, BMI, and PAL. 
Systolic blood pressure, diastolic blood pressure, and age 
(nonlinear) were positively associated with AI in univariate 
regression (Table 2). Table 3 shows the independent deter-
minants of AI based on the multiple regression analysis. 
PAL, male sex, and BMI were negatively associated with 
AI. Furthermore, a nonlinear positive association between 
AI and age and a linear positive association between systolic 
blood pressure and AI were observed. Airflow limitation 
was not independently associated with AI. Due to a high 
interrelationship between FEV
1
 %predicted and RV/TLC 
(r=-0.81, P,0.001), FEV
1
 %predicted and TLco (r=0.48, 
P,0.001), and systolic and diastolic blood pressure (r=0.76, 
P,0.001), respectively, RV/TLC, TLco, and diastolic blood 
pressure were removed from the model. Residual analysis 
of the final model did not show a violation of the regression 
assumptions. Multivariate regression of adjusted AI and PAL 
is displayed in Figure 3.
Discussion
This study investigated the impact of objectively measured 
PA on arterial stiffness in a heterogeneous group of COPD 
patients. The main finding of this study was that a lower PAL 
is an important determinant of arterial stiffness independent 
of other known confounders, such as age, sex, and systolic 
blood pressure. Airflow limitation was not independently 
associated with arterial stiffness.
Table 1 Patient characteristics
age, y 62 (7.5)
Male/female 89/35
BMI, kg/m2 24.9 (22.4/28.4)
Current smoker, N (%) 27 (22)
Pack years of smoking, N 39 (26.5/60.0)
systolic BP, mmhg 129 (15.8)
Diastolic BP, mmhg 81 (10.1)
FeV1, %predicted 35 (27.0/65.0)
FVC, %predicted 79 (18.6)
rV, %predicted 179 (125.0/225.0)
TlC, %predicted 115 (24.0)
rV/TlC 56 (13.0)
Tlco, %predicted 36 (15.0/55.0)
antihypertensivum, n (%) 65 (53)
statin, n (%) 44 (36)
laMa only, n (%) 8 (7)
laMa + gC, n (%) 2 (2)
laBa only, n (%) 5 (4)
laBa + gC, n (%) 13 (11)
laMa + laBa, n (%) 5 (4)
laMa + laBa + gC, n (%) 69 (56)
arterial hypertension, n (%) 54 (44)
CVD, n (%) 27 (22)
PaD, n (%) 12 (10)
CrP, mg/l 1.8 (0.9/4.0)
Pal 1.4 (1.3/1.5)
number of steps per day, n 4,149 (2,498.5/6,679.0)
augmentation index, % 26 (9.2)
Note: Values are median (quartiles) or mean (sD) unless otherwise stated.
Abbreviations: y, years; BMI, body mass index; BP, blood pressure; FeV1, forced 
expiratory volume in 1 second; FVC, forced volume capacity; rV, residual volume; TlC, 
total lung capacity; Tlco, diffusion capacity; laMa, long-acting muscarinic antagonist; 
laBa, long-acting beta-agonist; gC, glucocorticoids; CVD, cardiovascular disease; 
PaD, peripheral artery disease; CrP, c-reactive protein; Pal, physical activity level.
Table 2 Univariate regression analysis of possible predictors for 
aortic augmentation index
B 95% confidence 
interval
P-value
linear age
age, y 0.08 -0.14/0.30 0.452
nonlinear age
age, y 3.77 0.88/6.67 0.011*
age × age,  
y (squared term)
-0.03 -0.05/-0.01 0.013*
Male -7.12 -10.59/-3.64 ,0.001*
BMI, kg/m2 -0.44 -0.71/-0.17 0.002*
Current  
smoker, N
-0.05 -4.06/3.95 0.979
Pack years of  
smoking, N
0.39 -0.03/0.11 0.291
systolic blood  
pressure, mmhg
0.16 0.06/0.26 0.003*
Diastolic blood  
pressure, mmhg
0.33 0.17/0.48 ,0.001*
FeV1, %predicted -0.06 -0.14/0.01 0.089
FVC, %predicted -0.01 -0.10/0.07 0.772
rV/TlC, % 0.10 -0.02/0.23 0.098
arterial  
hypertension, n
-1.56 -4.89/1.77 0.355
CVD, n -2.33 -6.31/1.65 0.249
PaD, n -0.06 -5.64/5.53 0.984
CrP, mg/l 0.03 -1.14/0.21 0.699
Pal -11.72 -19.66/-3.78 0.004*
number of  
steps per day, n
-0.00 -0.00/0.00 0.502
Note: *P,0.05.
Abbreviations: y, years; BMI, body mass index; FeV1, forced expiratory volume 
in 1 second; FVC, forced volume capacity; rV, residual volume; TlC, total lung 
capacity; CVD, cardiovascular disease; PaD, peripheral artery disease; CrP, 
c-reactive protein; Pal, physical activity level.
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Pulse wave analysis-derived measures of arterial stiff-
ness (PWV and AI) have been shown to predict cardio-
vascular risk and mortality besides classic cardiovascular 
risk factors6,7,25 and are elevated in COPD patients.8,9 In 
a case-control study with 102 COPD patients and 103 
healthy controls, arterial stiffness was significantly higher 
in the COPD group compared to controls matched for age 
and smoking status.26 Previous studies investigated pos-
sible predictors of arterial stiffness that typically exists in 
COPD patients such as airflow limitation9,10,27 and systemic 
inflammation.9,27 Sabit et al9 found no association between 
AI and FEV
1
 in 75 stable COPD patients. Accordingly, 
Bhatt et al27 showed no significant differences in FEV
1
 
%predicted across PWV quartiles in 153 patients with 
COPD. In contrast, McAllister et al10 showed that PWV was 
higher in severe and very severe COPD patients than in those 
with mild to moderate COPD. Therefore, the influence of 
airflow limitation on arterial stiffness is still unclear due to 
the conflicting findings. Results from studies investigating 
systemic inflammation as another possible predictor for 
arterial stiffness in COPD patients have led to conflicting 
results. Systemic inflammation as an extra-pulmonary effect 
of COPD has been shown to increase the cardiovascular risk 
in COPD patients.28 In healthy individuals, arterial stiffness 
has been positively associated with different markers of 
systemic inflammation.29 In a COPD study evaluating the 
association between increased arterial stiffness and systemic 
inflammation, increased interleukin-6 was a predictor for 
arterial stiffness.9 However, there are other studies indicat-
ing no effect of systemic inflammation on arterial stiffness 
in COPD patients.11 In our study, c-reactive protein as a 
marker for systemic inflammation showed also no associa-
tion with arterial stiffness. The ECLIPSE study showed that 
systemic inflammation was present only in a 16% of the 
COPD patients.30 To further address this question, it would 
be helpful to study exclusively the subgroup of COPD 
patients with persistently elevated inflammatory biomarker 
levels who may constitute a distinct phenotype.
Physical inactivity is a characteristic feature of COPD 
patients.14 A lower level of PA is known to be a strong pre-
dictor for all-cause mortality in patients with COPD.31 Previ-
ous studies in healthy individuals indicated that individuals 
with a higher PAL had lower arterial stiffness compared to 
individuals with a lower PAL.32,33 In COPD patients, there 
is only one study investigating the relationship between PA 
and arterial stiffness. Stickland et al34 investigated the asso-
ciation between PWV and PA and exercise intolerance, in a 
study with 33 COPD patients without known cardiovascular 
risk factors. Arterial stiffness was significantly higher in 
the inactive COPD group as compared to the active group, 
whereas daily PA was not independently associated with 
PWV. In contrast, we found an independent association 
between arterial stiffness and PAL. Our results showed that 
an increase in PAL of 0.2 will lead to a decrease in AI of 
4%, which may correspond to a decrease in cardiovascular 
event rate of 13% based on studies evaluating AI as a pre-
dictor for cardiovascular risk.35 These conflicting findings 
might be due to the larger sample size in our study and the 
different patient characteristics. Whereas we included all 
COPD patients to obtain a clinically representative cohort, 
Stickland et al34 excluded patients with known cardiovascu-
lar disease, diabetes, vasoactive medications, obesity, and 
Table 3 Multiple regression analysis of possible predictors for 
aortic augmentation index
B 95% confidence 
interval
P-value
nonlinear age
age, y 2.74 0.10/5.38 0.042*
age × age,  
y (squared term)
-0.02 -0.04/-0.00 0.044*
Male/female -6.64 -9.9/-3.4 ,0.001*
BMI, kg/m2 -0.35 -0.62/-0.08 0.012*
systolic blood  
pressure, mmhg
0.19 0.10/0.29 ,0.001*
FeV1, %predicted 0.03 -0.05/0.10 0.474
Pal -9.32 -16.96/-1.68 0.017*
Note: *P,0.05.
Abbreviations: y, years; BMI, body mass index; FeV1, forced expiratory volume 
in 1 second; Pal, physical activity level.
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Figure 3 a scatterplot of aI and Pal adjusted for age, age × age (squared term), 
sex, BMI, systolic blood pressure, and FeV1 %predicted according to the final 
regression model is shown.
Notes: The regression line (black line) and confidence intervals (gray bar) are marked. 
The figure illustrates a decrease of the AI with increasing PAL in COPD patients.
Abbreviations: aI, augmentation index; Pal, physical activity level; BMI, body mass 
index; FeV1, forced expiratory volume in 1 second.
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severe inflammatory disorders. To date, there are only two 
studies investigating the effect of exercise training on arte-
rial stiffness in COPD.36,37 In a small case-controlled study 
with 17 COPD patients, Vivodtzev et al36 showed that after 
4 weeks of exercise training, arterial stiffness was reduced 
in the intervention group, whereas it remained unchanged in 
the control group. In a case-controlled study by Gale et al37 
aortic stiffness was also improved after a standard multi-
disciplinary pulmonary rehabilitation in 32 stable COPD 
patients. However, further studies are needed to investigate 
if the independent association between arterial stiffness and 
PAL is also modifiable by changes in PAL.
In accordance with previous studies performed in healthy 
subjects and patients with COPD, age and female sex were 
independently associated with a higher degree of arterial 
stiffness, whereas BMI showed an inverse independent 
association. A similar inverse relationship between AI and 
BMI has been documented in earlier studies.9,38 However, 
the pathophysiological background of this association is 
still unclear.
The current study has some limitations. The cross-sectional 
study design does not allow establishing a causal relationship 
between arterial stiffness and PAL in patients with COPD. 
The cohort is mainly representative for patient care in a 
university hospital. Therefore, predominantly patients with 
more advanced stages of COPD were included.
Conclusion
In conclusion, our findings suggest that in COPD patients, 
a higher PAL seems to favorably influence arterial stiffness 
and therefore may reduce cardiovascular risk.
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